JP2021531291A5 - - Google Patents
Info
- Publication number
- JP2021531291A5 JP2021531291A5 JP2021503007A JP2021503007A JP2021531291A5 JP 2021531291 A5 JP2021531291 A5 JP 2021531291A5 JP 2021503007 A JP2021503007 A JP 2021503007A JP 2021503007 A JP2021503007 A JP 2021503007A JP 2021531291 A5 JP2021531291 A5 JP 2021531291A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- pain
- substituted
- substituents independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18184716.1 | 2018-07-20 | ||
| EP18184716 | 2018-07-20 | ||
| PCT/EP2019/069593 WO2020016443A1 (en) | 2018-07-20 | 2019-07-19 | Difluoromethyl-phenyl triazoles as gaba receptor modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021531291A JP2021531291A (ja) | 2021-11-18 |
| JP2021531291A5 true JP2021531291A5 (enExample) | 2022-07-27 |
| JP7311583B2 JP7311583B2 (ja) | 2023-07-19 |
Family
ID=63014393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021503007A Active JP7311583B2 (ja) | 2018-07-20 | 2019-07-19 | Ｇａｂａ受容体モジュレーターとしてのジフルオロメチル－フェニルトリアゾール |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10941137B2 (enExample) |
| EP (1) | EP3823967B1 (enExample) |
| JP (1) | JP7311583B2 (enExample) |
| CN (1) | CN112424197B (enExample) |
| AR (1) | AR117615A1 (enExample) |
| BR (1) | BR102019014802A2 (enExample) |
| TW (1) | TW202019915A (enExample) |
| WO (1) | WO2020016443A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI901650B (zh) * | 2020-03-26 | 2025-10-21 | 匈牙利商羅特格登公司 | 啶及吡啶并〔３，４－ｃ〕嗒衍生物 |
| EP4149933B1 (en) * | 2020-05-13 | 2024-06-12 | F. Hoffmann-La Roche AG | New triazolyl derivatives as gaba a alpha5 pam |
| EP3971179A1 (en) * | 2020-09-22 | 2022-03-23 | Boehringer Ingelheim International GmbH | Difluoromethyl-pyridin-2-yl triazoles |
| CN116888115B (zh) * | 2020-08-05 | 2026-03-20 | 萨尼奥纳有限责任公司 | 二氟甲基-吡啶-2-基三唑 |
| EP3992188A1 (en) * | 2020-10-29 | 2022-05-04 | Boehringer Ingelheim International GmbH | Difluoromethyl-pyridin-2-yl triazoles |
| EP3950683A1 (en) * | 2020-08-05 | 2022-02-09 | Boehringer Ingelheim International GmbH | Difluoromethyl-pyridin-2-yl triazoles |
| CA3228655A1 (en) * | 2021-08-12 | 2023-02-16 | Shanghai SIMR Biotechnology Co., Ltd | Substituted triazole derivative, preparation method therefor, pharmaceutical composition thereof, and use thereof |
| HU231691B1 (hu) | 2021-09-29 | 2025-10-28 | Richter Gedeon Nyrt | GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok |
| CN116462664B (zh) * | 2022-03-08 | 2025-07-01 | 上海赛默罗生物科技有限公司 | 吡唑环类化合物、其制备方法、组合物及应用 |
| CN116854680A (zh) * | 2022-03-28 | 2023-10-10 | 上海赛默罗生物科技有限公司 | 异噁唑-杂环类衍生物、药物组合物和用途 |
| WO2024251133A1 (zh) * | 2023-06-05 | 2024-12-12 | 武汉人福创新药物研发中心有限公司 | 作为α5-GABAA受体调节剂的杂环化合物及其用途 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2623043A1 (en) | 2005-09-19 | 2007-04-12 | F. Hoffman-La Roche Ag | Isoxazolo derivatives as gaba a alpha5 inverse agonists |
| BRPI0617306A2 (pt) | 2005-10-11 | 2011-07-19 | Hoffmann La Roche | derivados de isoxazol |
| BRPI0618383A2 (pt) | 2005-11-09 | 2011-08-30 | Hoffmann La Roche | derivados de 3-aril-isoxazol-4-carbonil-benzofurano |
| BRPI0620146A2 (pt) | 2005-12-23 | 2011-11-01 | Hoffmann La Roche | derivados de aril-isoxazolo-4-il-oxadiazol, processo para a preparação dos referidos derivados, medicamento que os contém e usos de um desses derivados |
| JP4864982B2 (ja) | 2005-12-27 | 2012-02-01 | エフ．ホフマン−ラ ロシュ アーゲー | アリール−イソオキサゾール−４−イル−イミダゾ［１，５−ａ］ピリジン誘導体 |
| KR101121372B1 (ko) | 2005-12-27 | 2012-04-12 | 에프. 호프만-라 로슈 아게 | 아릴-이속사졸-4-일-이미다졸 유도체 |
| AU2007267692B2 (en) | 2006-05-24 | 2012-06-14 | Eli Lilly And Company | Compounds and methods for modulating FXR |
| CA2651857A1 (en) | 2006-05-31 | 2007-12-06 | F. Hoffmann-La Roche Ag | Aryl-4-ethynyl-isoxazole derivatives |
| EP1894924A1 (en) | 2006-08-29 | 2008-03-05 | Phenex Pharmaceuticals AG | Heterocyclic FXR binding compounds |
| EP1894928A1 (en) | 2006-08-29 | 2008-03-05 | PheneX Pharmaceuticals AG | Heterocyclic fxr binding compounds |
| BRPI0814718A2 (pt) | 2007-06-22 | 2015-02-24 | Hoffmann La Roche | Derivados de isoxazol-imidazol |
| CA2706990C (en) | 2007-12-04 | 2016-05-10 | F. Hoffmann-La Roche Ag | Isoxazolo-pyrazine derivatives |
| US7943619B2 (en) | 2007-12-04 | 2011-05-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyridazine derivatives |
| EP2227467B1 (en) | 2007-12-04 | 2014-12-31 | F. Hoffmann-La Roche AG | Isoxazolo-pyridine derivatives |
| EP2128158A1 (en) | 2008-05-26 | 2009-12-02 | Phenex Pharmaceuticals AG | Heterocyclic cyclopropyl-substituted FXR binding compounds |
| US8389550B2 (en) | 2009-02-25 | 2013-03-05 | Hoffmann-La Roche Inc. | Isoxazoles / O-pyridines with ethyl and ethenyl linker |
| US8222246B2 (en) | 2009-04-02 | 2012-07-17 | Hoffmann-La Roche Inc. | Substituted isoxazoles |
| US20100280019A1 (en) | 2009-04-30 | 2010-11-04 | Roland Jakob-Roetne | Isoxazoles |
| WO2010127976A1 (en) | 2009-05-05 | 2010-11-11 | F. Hoffmann-La Roche Ag | Isoxazole-pyridine derivatives |
| SG175869A1 (en) | 2009-05-05 | 2011-12-29 | Hoffmann La Roche | Isoxazole-thiazole derivatives as gaba a receptor inverse agonists for use in the treatment of cognitive disorders |
| AU2010244552A1 (en) | 2009-05-05 | 2011-09-29 | F. Hoffmann-La Roche Ag | Isoxazole-pyrazole derivatives |
| ES2467701T3 (es) | 2009-05-05 | 2014-06-12 | F. Hoffmann-La Roche Ag | Derivados de isoxazol-piridazina |
| AU2010244555A1 (en) | 2009-05-07 | 2011-11-03 | F. Hoffmann-La Roche Ag | Isoxazole-pyridine derivatives as GABA modulators |
| EP2289883A1 (en) | 2009-08-19 | 2011-03-02 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| NZ608592A (en) | 2010-11-05 | 2015-08-28 | Hoffmann La Roche | Use of active pharmaceutical compounds for the treatment of central nervous system conditions |
| US8742097B2 (en) * | 2010-11-09 | 2014-06-03 | Hoffmann-La Roche Inc. | Triazole compounds I |
| KR20130100348A (ko) * | 2010-11-09 | 2013-09-10 | 에프. 호프만-라 로슈 아게 | Gaba 수용체에 대한 리간드로서의 트라이아졸 유도체 |
| JP2014122161A (ja) | 2011-03-31 | 2014-07-03 | Astellas Pharma Inc | ピラゾール化合物 |
| CA2876778A1 (en) | 2012-06-26 | 2014-01-03 | Saniona Aps | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
| WO2014001278A1 (en) * | 2012-06-26 | 2014-01-03 | Aniona Aps | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
| WO2014001280A1 (en) * | 2012-06-26 | 2014-01-03 | Aniona Aps | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
| KR20150033679A (ko) * | 2012-06-26 | 2015-04-01 | 사니오나 에이피에스 | 페닐 트리아졸 유도체 및 이의 gabaa 수용체 복합체 조절용 용도 |
| UA125524C2 (uk) | 2016-12-08 | 2022-04-13 | Ф. Хоффманн-Ля Рош Аг | Ефірні похідні ізоксазолу як позитивні алостеричні модулятори рецептора гамк а альфа-5 |
-
2019
- 2019-07-18 BR BR102019014802A patent/BR102019014802A2/pt not_active Application Discontinuation
- 2019-07-19 US US16/516,398 patent/US10941137B2/en active Active
- 2019-07-19 WO PCT/EP2019/069593 patent/WO2020016443A1/en not_active Ceased
- 2019-07-19 CN CN201980047952.XA patent/CN112424197B/zh active Active
- 2019-07-19 TW TW108125527A patent/TW202019915A/zh unknown
- 2019-07-19 EP EP19742592.9A patent/EP3823967B1/en active Active
- 2019-07-19 JP JP2021503007A patent/JP7311583B2/ja active Active
- 2019-07-19 AR ARP190102039A patent/AR117615A1/es not_active Application Discontinuation
-
2021
- 2021-01-27 US US17/160,285 patent/US20210147393A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU652753B2 (en) | 5-aryl pyrimidine, processes for its production and use as treatment for CNS disorders | |
| RU2007139541A (ru) | Производные хромана и хромена и их применение | |
| JP2017531020A5 (enExample) | ||
| CA2475619C (en) | Piperidine derivatives | |
| CN118576586A (zh) | 治疗神经和精神疾病的方法 | |
| AU2025267332A1 (en) | Psychotropic agents and uses thereof | |
| JP2010502722A5 (enExample) | ||
| BR122017023795B8 (pt) | método para preparação de composição farmacêutica | |
| JP2009538853A5 (enExample) | ||
| RU2015143466A (ru) | Нейроактивные стероиды и способы их применения | |
| JP2010538001A5 (enExample) | ||
| RU2009147708A (ru) | Производные оксадиазола и их применение в качестве потенцирующих средств метаботропных глутаматных рецепторов-842 | |
| JP2015521642A5 (enExample) | ||
| CN110366555A (zh) | 甾族类衍生物调节剂、其制备方法和应用 | |
| JP2014526469A5 (enExample) | ||
| MX2017013483A (es) | Compuestos y su uso como inhibidores de ?-secretasa 1 (bace1). | |
| RU2010126622A (ru) | Конденсированные с арилом и гетероарилом имидазо[1, 5-а]пиразины в качестве ингибиторов фосфодиэстеразы 10 | |
| RU2006105782A (ru) | Производные 1-сульфонилиндола, их получение и их применение в качестве лигандов 5-нт-6 | |
| AU2014231722B2 (en) | Salts, co-crystals, and polymorphs of an anxiolytic compound | |
| JP2019524844A5 (enExample) | ||
| JP2017536409A5 (enExample) | ||
| JP2023536511A5 (enExample) | ||
| EP1682549B1 (en) | Imidazo[1,2-a]pyridine anxiolytics | |
| IL288271B2 (en) | Pharmaceutically acceptable salts of [2-(3-fluoro-5-methanesulfonylphenoxy)ethyl](propyl)amine and their uses | |
| JP2011511818A5 (enExample) |